Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. on March 31, 2026, covering a pyrimido pyrimidinone compound that inhibits PD-L1 expression for cancer treatment. The patent includes 9 claims and names 8 inventors including Young Jun Park and Sung Jun Park.

View original document View source feed page

What changed

USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. for a pyrimido pyrimidinone compound effective as a PD-L1 inhibitor for cancer treatment or prevention. The patent (Application No. 18245395, filed September 15, 2021) contains 9 claims and is classified under CPC C07D 487/04.

No immediate compliance action is required by regulated entities. This is a routine patent grant that establishes intellectual property rights for the assignee. Third parties seeking to use or develop similar compounds should conduct freedom-to-operate analyses and respect the patent's claim scope.

Source document (simplified)

← USPTO Patent Grants

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

Grant US12590098B2 Kind: B2 Mar 31, 2026

Assignee

AXCESO BIOPHARMA CO., LTD.

Inventors

Young Jun Park, Sung Jun Park, Hyebin Yoo, Hyunnam Song, Si-Eun Yun, Sojin Park, Joon Woo Kim, Sung Il Yoon

Abstract

Diclosed are a pyrimido pyrimidinone compound having an effect of inhibiting PD-L1 expression, a pharmaceutical composition containing the pyrimido pyrimidinone compound as an active ingredient, and uses of the compound or composition. The pyrimido pyrimidinone compound can be effectively used for the treatment or prevention of cancer.